GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Equity-to-Asset

Tibet Aim Pharm (SZSE:002826) Equity-to-Asset : 0.80 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tibet Aim Pharm's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥749.2 Mil. Tibet Aim Pharm's Total Assets for the quarter that ended in Mar. 2024 was ¥938.5 Mil. Therefore, Tibet Aim Pharm's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.80.

The historical rank and industry rank for Tibet Aim Pharm's Equity-to-Asset or its related term are showing as below:

SZSE:002826' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62   Med: 0.8   Max: 0.87
Current: 0.8

During the past 10 years, the highest Equity to Asset Ratio of Tibet Aim Pharm was 0.87. The lowest was 0.62. And the median was 0.80.

SZSE:002826's Equity-to-Asset is ranked better than
81.62% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:002826: 0.80

Tibet Aim Pharm Equity-to-Asset Historical Data

The historical data trend for Tibet Aim Pharm's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Equity-to-Asset Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.78 0.76 0.87 0.73

Tibet Aim Pharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.75 0.77 0.80 0.80

Competitive Comparison of Tibet Aim Pharm's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Equity-to-Asset falls into.



Tibet Aim Pharm Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Tibet Aim Pharm's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=745.294/1018.205
=0.73

Tibet Aim Pharm's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=749.232/938.543
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm  (SZSE:002826) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Tibet Aim Pharm Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines